药物合成与制剂工程研究团队

团队简介：本团队现有教授1人，副教授3人，讲师1人。实验室研究方向包括:抗肿瘤与抗病毒领域的新药研发、天然产物的分离与活性评价以及药物分子的多晶型研究等。实验室至今完成的项目包括绿色农药（螺威植物杀螺剂改进及拓展、烟草花叶病毒防治剂）研发、抗肿瘤干细胞研究——选择性mTOR抑制剂的设计合成与筛选、硫酸氨基葡萄糖的生产工艺开发、抗寄生虫黄连素衍生物的合成,评估及机理研究等。近五年来，实验室发表SCI论文40余篇，获批专利6项,培养研究生30余人，其中5人荣获国家奖学金，8人毕业论文荣获优秀硕士论文，5人荣获优秀硕士毕业研究生。

团队负责人

龙思会，博士，教授、楚天学子特聘教授，美国化学会和美国药剂科学家协会会员。其研究方向包括药物分子的多晶型研究、抗肿瘤药物的设计与合成等。迄今已培养30多位研究生，其中两人获得了美国著名高校的全额奖学金赴美深造。其育人理念为:志存高远，脚踏实地;才兼文理，学贯中西;勤于思考，终身学习。

团队成员

代表性论文

Zhoujin, Y.; Li, Y.; Liang, P-Y.; Zhou, P-P.; Parkin, S.; Li, T.; Yu, F.; Long, S. anti/gauche Conformations Lead to the Polymorphism in Homologous Phenylalkylamino-nicotinic Acids Crystal Growth & Design ASAP

Li, J.; Wu, K.; Li, X.; Long, S.; Zhou, Z.; Zhao, Y.; Jia, R.; Song, P.; Liu, J.; Liu, B. Quantifying induction/inhibition effects on fuzuloparib using a Physiologically Based Pharmaco-Kinetic(PBPK) model, Journal of Clinical and Experimental Pathology, 2022, 105(1), 229.

Zhu, R.; He, Q.; Li, Z.; Ren, Y.; Liao, Y.; Zhang, Z.; Dai, Q.; Wan, C.; Long, S.; Kong, L.; Fan, W.; Yu, W. ROS-cleavable diselenide nanomedicine for NIR-controlled drug release and on-demand synergistic chemo-photodynamic therapy, Acta Biomaterialia, 2022, 153(22)，442.

Zhao, X.; Liu, Z.; Liu, H.; Guo, J.; Long, S. Hybrid molecules based on caffeic acid as potential therapeutics: A focused review, European Journal of Medicinal Chemistry, 2022, 243, 114745.

Zhoujin, Y.; Li, Y.; Liang, P.Y.; Zhou, P.P.; Parkin, S.; Li, T.; Yu, F.; Long, S. Effect of homologation on the polymorphism of anthranilic acids, Crystal Growth & Design, 2022, 22 (10), 6207.

Dong, B.; Liu, Y.; Yang, P.; Sang, D.; Tian, J.; Li, L.; Long, S. Denitrogenative cleavage of benzotriazoles and benzotriazinones, and selective N-desulfonylation of benzotriazoles by aluminum halides, Tetrahedron Letters, 2022, 103, 153965.

Xie, D.; Xu, X.; Long, S.; Tang, X. Y.; Wang, L. Synthesis of (2-(quinolin-2-yl)phenyl)carbamates by a one-pot Friedel-CraftsReaction/Oxidative Umpolung Aza-Grob fragmentation sequence, Journal of Organic Chemistry, 2022, 87(12), 7852.

Tao, Y.; Liu, X.; Zhoujin, Y.; Zhou, P. P.; Parkin, S.; Li, T.; Guo, J.; Yu, F.; Long, S. Conformational flexibility and substitution pattern lead to polymorphism of 3-tethyl-2-(phenylamino)benzoic acid, CrystEngComm, 2022, 24(17), 3217.

Liu, Z.; Zhou, X.; Wu, F.; Liu, Z. W. Microwave-assisted preparation of activated carbon modified by Zinc Chloride as a packing material for column separation of saccharides, ACS Omega, 2020, 5(17), 10106.

Ren, Y.; Li, L.; Wan, L.; Huang, Y.; Cao, S. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists, Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37(1), 606.

Ren, Y.; Chen, Y.; Cao, S. Targeted inhibition of the endonuclease activity of influenza polymerase acidic proteins, Future Medicinal Chemistry, 2022, 14(8), 571.

Cao, S.; Chen, Y.; Ren, Y.; Feng, Y.; Long, S. GLUT1 biological function and inhibition: research advances, Future Medicinal Chemistry, 2021, 13(14), 1227.

Ren, Y.; Long, S.; Cao, S. Molecular docking and virtual screening of an influenza virus inhibitor that disrupts protein-protein interactions,Viruses, 2021, 13(11), 2229.

Guo, J.; Yang, Y.; Wang, N.; Liu, Z. Z. Synthesis and cytotoxicity screening of derivatives of the simplified ecteinascidin pentacyclic skeleton as anticancer agents, Tetrahedron Letters, 2018, 59(33), 3202.

授权专利

龙思会等.一种吡啶季铵盐类化合物及其制备方法与应用,ZL202010066131.5, CN111205221B。

曹爽等.一种三唑并嘧啶类化合物及其制备方法和应用，ZL202010287331.3, CN111333655A。

曹爽等.新型噻唑衍生物类化合物、其制备方法、药物组合物及其制药用途，ZL201410242439.A, CN105461738A。

曹爽等.苯并噻唑类化合物在抗肿瘤方面的用途，ZL201410128295.8, CN103960822A。

曹爽等.雷帕霉素衍生物制备方法以及其在药学方面的用途，ZL201410242439.5, CN105461738A。